11.14 USD
↘ 0.55 (4.70%)AT CLOSE (11:59 AM EDT)
Q32 Bio Inc. Common Stock
QTTBNASDAQ • USD
11.33
↗ 0.18 (1.66%)
POST MARKET (AS OF 07:55 PM EDT)
Post Market
AS OF 07:55 PM EDT
11.33
↗ 0.18 (1.66%)
Market: CLOSED
Shares of Q32 Bio Inc. Common Stock (QTTB) are trading at $11.13. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (31.9%) and a bullish Golden Cross on the moving averages. On the valuation side, QTTB appears attractively valued relative to sector peers across key multiples.
Technical & fundamental data as of Sep 9, 2026.
Open?$11.61
High?$11.95
Low?$11.07
Prev. Close?$11.69
Volume?488.9K
Avg. Volume?456.5K
VWAP?$11.43
Rel. Volume?1.07x
Bid / Ask
Bid?$9.50 × 100
Ask?$12.66 × 100
Spread?$3.16
Midpoint?$11.08
Valuation & Ratios
Market Cap?348.0M
Shares Out?29.8M
Float?12.3M
Float %?51.9%
P/E Ratio?10.30
P/B Ratio?3.29
EPS?$1.13
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Address
830 WINTER STREET
WALTHAM, MA 02451
Phone: 781-999-0232
WALTHAM, MA 02451
Phone: 781-999-0232
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?65
Short Sent.?16
Piotroski F-Score?0/9Weak
Altman Z-Score?20.44Safe
Confidence?48%Low
Short InterestSqueeze Risk
Short % of Float?25.49%Squeeze Risk
Short Interest?3.1M
Days to Cover?6.9
Free Float12.3M
Avg Daily Volume457.5K
Settlement Date2026-08-14
Financial Health
Current Ratio?20.30Strong
Quick Ratio?20.30Strong
Cash Ratio?19.68Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score80/100
P/E?10.3CHEAP▾
Peers100
S&P97
P/B?3.29FAIR▾
Peers100
S&P51
P/S?6.48FAIR▾
Peers100
S&P19
P/FCF?N/A▾
EV/EBITDA?11.1CHEAP▾
Peers100
S&P74
EV/Sales?4.50FAIR▾
Peers100
S&P40
Returns & Efficiency
ROE?31.9%STRONG▾
Peers50
S&P81
ROA?29.2%STRONG▾
Peers50
S&P97
Cash Flow & Enterprise
FCF?$-19828000
Enterprise Value?$241.7M
Fundamentals ratios updated end of day